ArticleNanoscale advances2020
Biokinetics and clearance of inhaled gold ultrasmall-in-nano architectures.
Article in Nanoscale advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Inhaled Targeted Nano-Drug Delivery Systems for COPD: Precision Solutions to Clinical Barriers.International journal of nanomedicine · 2026Review
- Inhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review.Pharmaceutics · 2025Review
- Inorganic Nanomaterials Meet the Immune System: An Intricate Balance.Advanced healthcare materials · 2025Review
- Targeted Nanoclusters for Intratracheal Delivery in Intraoperative Imaging of Lung Adenocarcinoma.International journal of nanomedicine · 2025Article
- Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation.RSC advances · 2023Review
- Harnessing Nuclear Energy to Gold Nanoparticles for the Concurrent Chemoradiotherapy of Glioblastoma.Nanomaterials (Basel, Switzerland) · 2023Article
- Copper nano-architecture topical cream for the accelerated recovery of burnt skin.Nanoscale advances · 2023Article
- Article
- Ultrasmall-in-Nano: Why Size Matters.Nanomaterials (Basel, Switzerland) · 2022Review
- The Fate of Intranasally Instilled Silver Nanoarchitectures.Nano letters · 2022Article
- Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment.iScience · 2022Article
- Exposure to Nickel Oxide Nanoparticles Induces Acute and Chronic Inflammatory Responses in Rat Lungs and Perturbs the Lung Microbiome.International journal of environmental research and public health · 2022Article
- Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors.Pharmaceutics · 2021Article
- A Standard Protocol for the Production and Bioevaluation of EthicalACS pharmacology & translational science · 2021Article
- Antimicrobial Nano-Agents: The Copper Age.ACS nano · 2021Review
- Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.Cancers · 2021Article
- A Cost-Effective Approach for Non-Persistent Gold Nano-Architectures Production.Nanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among an organism's entry portals, the respiratory tract is one of the most promising routes for non-invasive administration of therapeutics for local and systemic delivery. On the other hand, it is the subtlest to protect from environmental pollution and microbial occurrences. Here, the biokinetics, distribution, and clearance trends of gold ultrasmall-in-nano architectures administered through a single intranasal application have been quantitatively evaluated. Apart from reaching the lung parenchyma, the (bio)degradable nano-architectures are able to translocate as well to secondary organs and be almost completely excreted within 10 days. These findings further support the clinical relevance of plasmonic nanomaterials for oncology and infectious disease treatment and management. Notably, this investigation also provides crucial information regarding the associated risks as a consequence of the pulmonary delivery of nanoparticles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.